BACKGROUND
Brain metastases are a common and serious consequence for patients with renal cell carcinoma. This study aimed to determine if survival has changed since the introduction of current therapies, identify prognostic factors, update the prognostic index (the Renal Graded Prognostic Assessment [GPA]) in the conte...
P. Sperduto, F. Johri, Hany Soliman et al.· The Lancet Oncology· 0 citations
Cancer is the second leading cause of death in low- and middle-income countries (LMICs). Primary tumors of the brain and central nervous system (CNS) represent key drivers of global cancer burden, and the South Asian Association for Regional Cooperation (SAARC) countries make up a significant proportion of this c...
Abstract Background Real-world outcomes after stereotactic radiosurgery (SRS) for brain metastases across the full burden spectrum are limited. We tested whether overall survival (OS) in higher-burden lesion groups is non-inferior to a 5-10 lesion reference and characterized salvage patterns, including whole-brain radi...
Drew T. Bergman, M. Parker, H. Walch et al.· Neuro-Oncology Advances· 0 citations
PURPOSE
Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era.
METHO...
C. Kinslow, G. Minniti, P. Brown et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.